UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

PloS one, 2023-03, Vol.18 (3), p.e0282512-e0282512

2023

Volltextzugriff (PDF)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Cancers, 2019-05, Vol.11 (6), p.737

2019

Volltextzugriff (PDF)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

British journal of cancer, 2021-03, Vol.124 (7), p.1249-1259

2021

Volltextzugriff (PDF)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Molecular cancer, 2023-10, Vol.22 (1), p.1-175, Article 175

2023

Volltextzugriff (PDF)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Molecular cancer, 2014-06, Vol.13 (1), p.157-157, Article 157

2014

Volltextzugriff (PDF)

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors

Life (Basel, Switzerland), 2023-02, Vol.13 (3), p.608

2023

Volltextzugriff (PDF)

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

International journal of molecular sciences, 2021-04, Vol.22 (8), p.3822

2021

Volltextzugriff (PDF)

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients

International journal of molecular sciences, 2020-01, Vol.21 (3), p.962

2020

Volltextzugriff (PDF)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Translational oncology, 2024-11, Vol.49, p.102073, Article 102073

2024

Volltextzugriff (PDF)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BMC cancer, 2018-10, Vol.18 (1), p.965-965, Article 965

2018

Volltextzugriff (PDF)

A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts

Proteomes, 2018-11, Vol.6 (4), p.45

2018

Volltextzugriff (PDF)

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

Investigational new drugs, 2019-06, Vol.37 (3), p.441-451

2019

Volltextzugriff (PDF)

FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures

The AAPS journal, 2022-10, Vol.24 (6), p.108, Article 108

2022

Volltextzugriff (PDF)

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Investigational new drugs, 2018-08, Vol.36 (4), p.581-589

2018

Volltextzugriff (PDF)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Cancers, 2019-02, Vol.11 (2), p.197

2019

Volltextzugriff (PDF)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

Therapeutic advances in medical oncology, 2020-01, Vol.12, p.1758835919897546-1758835919897546

2020

Volltextzugriff (PDF)

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models

PloS one, 2017-05, Vol.12 (5), p.e0177058-e0177058

2017

Volltextzugriff (PDF)

Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1773-1773

2020

Volltextzugriff (PDF)

Abstract P2-13-39: Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-39

2022

Volltextzugriff (PDF)

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-28

2022

Volltextzugriff (PDF)

Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-13-36

2022

Volltextzugriff (PDF)

Abstract B034: Targeting the HER family/Src pathways in ovarian cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (5_Supplement_2), p.B034-B034

2024

Volltextzugriff (PDF)

Abstract B095: Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.B095-B095

2023

Volltextzugriff (PDF)

Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-03-20

2020

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(98)
Berichte
(1)
Reviews
(1)

Sprache

Englisch
(99)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(54)
Humans
(31)
Female
(21)
Male
(15)
Animals
(12)
Breast Cancer
(12)
Oncology
(12)
Amino Acid Sequence
(10)
Endocrinology & Metabolism
(10)
Molecular Sequence Data
(10)
Adult
(9)
Biochemistry & Molecular Biology
(9)
Biological And Medical Sciences
(9)
Cancer Therapies
(9)
Fundamental And Applied Biological Sciences. Psychology
(8)
Middle Aged
(8)
Patients
(8)
Proteins
(8)
Tumors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2 -Mutated Breast Cancer

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Abstract 1773: Targeting HER2 and Src in HER2-driven ovarian and esophagogastric cancers

Abstract P2-13-39: Investigation of neratinib and endocrine therapy combinations in HER2 positive breast cancer models

Abstract P2-13-28: Inhibiting retinoic acid receptor signalling enhances the effect of neratinib in HER2 positive breast cancer cell lines

Abstract P2-13-36: Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+ breast cancer model

Abstract B034: Targeting the HER family/Src pathways in ovarian cancer

Abstract B095: Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models

Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

Suchergebnisse filtern